Meaningful symptomatic change in patients with myelofibrosis from the SIMPLIFY studies

This study determined the meaningful change threshold (MCT) for two momelotinib phase III trials, SIMPLIFY-1 and SIMPLIFY-2.

Source: Value in Health - February 2, 2024 Category: International Medicine & Public Health Authors: Stacie Hudgens, Srdan Verstovsek, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal McLornan, Mary Frances McMulllin, Jean-Jacques Kiladjian, Lynda Foltz, Uwe Platzbecker, Maria Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, An Source Type: research